Press releases
Browse US-specific press releases here.
Please visit our Global website for access to global press releases dating back to 2009.
-
GSK changes sales representative incentive program
We are announcing changes to our incentive program for sales representatives in certain countries.
-
GSK announces approval of Shingrix in China for prevention of shingles in adults aged 50 and over
National Medical Products Administration has approved Shingrix for the prevention of shingles (herpes zoster) in adults aged 50 or older.
-
Save the Children Announces $1.5 Million Grant from GSK to Enhance Disaster Relief
GSK will donate $1.5 million over three years to help enhance the global nonprofit’s ability to respond to disasters in the United States.
-
Nucala (mepolizumab) receives positive CHMP opinion for new self-administration options
Nucala (mepolizumab) receives positive CHMP opinion for new self-administration options
-
Nucala (mepolizumab) gains FDA approval for two new self-administration options
Nucala (mepolizumab) gains FDA approval for two new self-administration options
-
GSK joins forces with the University of California to advance genomic research and improve drug discovery
New ‘Laboratory for Genomics Research’ unites CRISPR pioneers with industry expertise to help unravel mysteries of the human genome
-
GSK announces phase III start for its anti GM-CSF antibody, otilimab, in patients with rheumatoid arthritis (RA)
First phase III program in RA to include head-to-head comparisons with current treatments across all pivotal studies...
-
ViiV Healthcare announces start of first-ever study to identify and evaluate approaches to implementing its once-monthly injectable HIV treatment in clinical practice
The long-acting injectable regimen has been granted Priority Review status by the FDA, with a target approval date set for December 29, 2019
-
ViiV Healthcare announces phase III study meets primary endpoint, demonstrating the ability to control HIV-1 with the 2-drug regimen Dovato (dolutegravir plus lamivudine) in virally suppressed patients switching from a TAF-containing, 3-drug regimen
Week 48 results from the TANGO study will be presented this month at 10th International AIDS Society Conference on HIV Science (IAS 2019).
-
IAS 2019: ViiV Healthcare showcasing innovation in HIV science
Data presented challenging the current treatment paradigm, investigating new options to meet the evolving needs of people living with HIV
-
GSK announces positive headline results in Phase 3 PRIMA study of ZEJULA (niraparib) for patients with ovarian cancer in the first line maintenance setting
Niraparib demonstrates significant improvement in progression free survival for women regardless of their biomarker status
-
GSK ships 2019-20 seasonal influenza vaccines for US market
GSK will begin shipping its quadrivalent influenza vaccines to US healthcare providers and pharmacies for the 2019-20 flu season.
-
ViiV Healthcare presents positive 96-week data from phase III study of investigational fostemsavir in heavily treatment-experienced patients with HIV at IAS 2019
Week 96 data from BRIGHTE study of first-in-class fostemsavir continue to show improvement in virologic suppression and immunologic response
-
GlaxoSmithKline plc appoints Jonathan Symonds as Non-Executive Chairman of the Board of Directors
GlaxoSmithKline plc appoints Jonathan Symonds as Non-Executive Chairman of the Board of Directors
-
GSK delivers sales and earnings growth in Q2 2019
Total EPS 19.5p, +>100% AER, +>100% CER; Adjusted EPS 30.5p +9% AER, +4% CER
-
ViiV Healthcare presents GEMINI 1 & 2 studies through Week 96 showing 2-drug regimen of dolutegravir plus lamivudine continues to demonstrate high efficacy rates and no cases of treatment emergent resistance
ViiV Healthcare presents GEMINI 1 & 2 studies
-
ViiV Healthcare announces positive Week 48 results in first study to evaluate treatment switch from TAF-containing regimen with three or more drugs to 2-drug regimen of dolutegravir/lamivudine for HIV-1 infection
Data from the TANGO study presented at the 10th International AIDS Society Conference on HIV Science (IAS 2019)
-
ViiV Healthcare submits regulatory application to European Medicines Agency for investigational cabotegravir to be used in combination with rilpivirine as the first monthly, injectable treatment for HIV
ViiV Healthcare submits regulatory application to European Medicines Agency
-
GSK completes transaction with Pfizer to form new world-leading Consumer Healthcare Joint Venture
GSK has completed its transaction with Pfizer to combine their consumer healthcare businesses into a world-leading Joint Venture.
-
GSK grants exclusive technology license for clinical-stage Ebola vaccines to Sabin Vaccine Institute
Transfer from GSK and partnership with NIAID will enable Sabin to advance development of the candidate vaccines
